Prostate Cancer Tumour Features on Template Prostate-mapping Biopsies: Implications for Focal Therapy  by Singh, Paras B. et al.
E U RO P E AN URO L OG Y 6 6 ( 2 0 1 4 ) 1 2 – 1 9
avai lable at www.sciencedirect .com
journal homepage: www.europeanurology.comPlatinum Priority – Prostate Cancer
Editorial by Luke Dixon, Matthew Brown and Benjamin Challacombe on pp. 20–21 of this issue
Prostate Cancer Tumour Features on Template Prostate-mapping
Biopsies: Implications for Focal TherapyParas B. Singh a, Chukwuemeka Anele b, Emma Dalton b, Omar Barbouti b, Daniel Stevens c,
Pratik Gurung a, Manit Arya d,e, Charles Jameson f, Alex Freeman f, Mark Emberton a,d,
Hashim U. Ahmed a,d,*
aDivision of Surgery and Interventional Sciences, University College London, London, UK; bMedical School, University College London, London, UK; cNuffield
Department of Surgical Sciences, University of Oxford, Oxford, UK; dDepartment of Urology, University College London Hospitals NHS Foundation Trust,
London, UK; eBarts Cancer Institute, Queen Mary, University of London, London, UK; fDepartment of Histopathology, University College London Hospitals
NHS Foundation Trust, London, UKArticle info
Article history:
Accepted September 25, 2013
Published online ahead of
print on October 6, 2013
Keywords:
Prostate cancer
Biopsy
Diagnosis
Pathology
Surgery
Therapy
Please visit
www.eu-acme.org/
europeanurology to read and
answer questions on-line.
The EU-ACME credits will
then be attributed
automatically.
Abstract
Background: Focal therapy is being offered as a viable alternative formenwith localised
prostate cancer (PCa), but it is unclear which men may be suitable.
Objective: To determine the proportion of men with localised PCa who are potentially
suitable for focal therapy.
Design, setting, and participants: Our institutional transperineal template prostate-
mapping (TTPM) biopsy registry of 377 men from 2006 to 2010 identiﬁed 291 consecu-
tive men with no prior treatment.
Intervention: TTPM biopsies using a 5-mm sampling frame.
Outcome measurements and statistical analysis: Suitability for focal therapy required
the cancer to be (1) unifocal, (2) unilateral, (3) bilateral/bifocal with at least one
neurovascular bundle avoided, or (4) bilateral/multifocal with one dominant index
lesion and secondary lesions with Gleason 3 + 3 and cancer core involvement
3 mm. Binary logistic regressionmodelling was used to determine variables predictive
for focal therapy suitability.
Results and limitations: The median age was 61 yr, and the median prostate-speciﬁc
antigen was 6.8 ng/ml. The median total was 29 cores, with a median of 8 positive cores.
Of 239 of 291menwith cancer, 29% (70men), 60% (144men), and 8% (20men) had low-,
intermediate-, and high-risk PCa, respectively. Ninety-two percent (220 men) were
suitable for one form of focal therapy: hemiablation (22%, 53 men), unifocal ablation
(31%, 73 men), bilateral/bifocal ablation (14%, 33 men), and index lesion ablation (26%,
61 men). Binary logistic regression modelling incorporating transrectal biopsy param-
eters showed no statistically signiﬁcant predictive variable. When incorporating TTPM
parameters, only T stage was a signiﬁcant negative predictor for suitability ( p = 0.001)
(odds ratio: 0.001 [95% conﬁdence interval, 0.000–0.048]). Limitations of the study
include potential selection bias caused by tertiary referral practise and lack of long-term
results on focal therapy efﬁcacy.
Conclusions: Focal therapy requires an accurate tool to localise individual cancer lesions.
When such a test, TTPM biopsy, was applied tomenwith low- and intermediate-risk PCa,
most of the men were suitable for a tissue preservation strategy.
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Localised prostate cancer (PCa) treatment currently involves
surgery or radiotherapy applied to the whole prostate
regardless of the location or volumeof individual PCa lesions.
Although there is a survival benefit from this approach in
menwith intermediate- andhigh-riskdisease, radicalwhole-
gland therapies are associatedwith a significant risk of rectal
complications, incontinence, and impotence [1,2]. Tissue-
preserving focal therapy, inwhichonlyareasofknowncancer
are targeted, may improve the therapeutic ratio [3–7]. A
number of early-phase studies have shown that preservation
of genitourinary function canbehigh following focal therapy,
althoughcancer control in themediumand long termisyet to
be fully evaluated [8–11].
One of the key challenges with focal therapy is to
accurately identify the population of men who are
potentially suitable for tissue preservation. Some practi-
tioners have argued that focal therapy is an alternative in
men suitable for active surveillance [3,5,12], while others
have argued that focal therapy should be investigated as a
potential alternative to radical therapy in those men likely
to benefit from treatment [4,6,12,13]. This argument
incorporates the concept of ablating the index cancer
lesion, which usually harbours the highest grade and largest
cancer volume [14]. A number of ethics committee–
approved trials are currently recruiting men with interme-
diate- and high-risk disease and treating them in an index
lesion–ablative manner [15–17].
Therefore, the population of men who are potentially
eligible for focal therapy is likely to vary with respect to risk
group and is dependent on the focal therapy strategy.
Studies using whole-mount prostatectomy specimens to
estimate this population might incorporate selection bias,
since men would have chosen surgery rather than any
number of other treatment modalities. We sought to
evaluate the proportion of men suitable for focal therapy
based on transperineal template prostate-mapping (TTPM)
biopsies, as this test can be applied to all men prior to
treatment.
2. Methods
This study received exemption from ethics committee approval from
the University College London Hospitals Joint Research Ofﬁce. Our
institutional TTPM biopsy registry includes all cases having this
procedure. The majority of these patients were tertiary referrals to our
institution with previous transrectal ultrasound–guided biopsies.
TTPM biopsies were conducted using a method previously described,
with cores taken every 5 mm throughout the prostate using a template
grid (Fig. 1) [18]. Antibiotic prophylaxis was used with single-dose
cefuroxime, gentamicin, and metronidazole at the time of induction.
The complications were assessed on immediate postoperative ﬁndings
and any hospital readmissions and were enquired of the patient at the
4–6-wk follow-up visit. The cancer risk group was determined using
the US National Comprehensive Cancer Network (NCCN) guidelines.
Locoregional radiologic staging was performed using prostate
magnetic resonance imaging (MRI), and distant metastases were
ruled out using a pelvic MRI and radioisotope bone scan in any man
with a Gleason score 7 on any histology, prostate-speciﬁc antigen10 ng/ml, or clinical/MRI T stage T3a. The T stage was based on MRI
characteristic only and not on histology [19].
Toxicity data were collected retrospectively through review of clinic
notes and are reported for completeness, although they may be subject
to recall bias. Criteria used to decide suitability for focal therapy were
those used in prospective ethics committee–approved trials actively
recruiting during the period of this study, with pathologic tumour
features characterised according to a combination of cancer core length
and Gleason grade [20] (Fig. 2). We have reported the results of two of
these studies [9,11]. A third trial treating the index lesion is currently
closed for analysis [18]. Our current multicentre focal therapy trial
incorporates all these focal therapy strategies and will aim to recruit
150 men [20].
In summary, suitability for focal therapy required the cancer to
be (1) unifocal, (2) unilateral, (3) bilateral/bifocal with at least one
neurovascular bundle avoided, or (4) bilateral/multifocal with one
dominant index lesion and secondary lesions with Gleason 3 + 3 and
cancer core involvement 3 mm. The avoidance of the neurovascular
bundle was based on ensuring that the posterior left or right quadrant of
prostate tissue was not ablated. We accept that the neurovascular
bundle is not a discrete bundle but has a more complex diffuse anatomic
distribution. We felt that the avoidance of a posterior quadrant at least
would avoid most of the ipsilateral nerves in question.
Because of the nonparametric nature of the data, a chi-square test or
Spearman rank order for correlation was used, depending on expected
values in the two-by-two tables. Cancer risk groups, in addition, were
dichotomised at the low/intermediate and intermediate/high thresholds
to reﬂect two schools of thought about the placement of focal therapy.
First, some practitioners believe that focal therapy is an alternative for
only those men suitable for active surveillance. Second, others have
argued that focal therapy is an alternative for men with clinically
signiﬁcant cancer as a strategy that might overcome the harms of
treatment but retain the cancer control beneﬁts. A binary logistic
regression model was also used, since the predictor variables were a
combination of continuous and categorical variables and not normally
distributed. Each logistic regressionmodel used nine predictor variables.
All tests were two-tailed and performed within SPSS statistical software
v.17.0 (2010; IBM Corp., Armonk, NY, USA), and signiﬁcance was deﬁned
as a p value <0.05.
3. Results
An unselected cohort of 377 men referred to our institution
underwent TTPM biopsy between 2006 and 2010; of these
men, 291 had no previous treatment and formed our cohort
for analysis (Fig. 3, Tables 1 and 2). The side-effects of TTPM
included perineal ecchymosis in 100% of the men (291 of
291); mild, self-resolving haematuria in most; haematuria
requiring admission in 2% (6 of 291); urinary retention in 7%
(20 of 291); urinary tract infection in 1% (3 of 291); scrotal
skin cellulitis in 0.3% (1 of 291); and no sepsis. We did not
routinely collate data on erectile dysfunction at baseline or
follow-up, so the actual number with haematospermia is
unknown.
Ninety-two percent ofmenwith cancer (220 of 239men)
on TTPM biopsy were suitable for at least one form of focal
therapy: hemiablation (22%, 53 of 239 men), unifocal
ablation (31%, (73 of 239 men), bilateral/bifocal ablation
(14%, 33 of 239 men), and index lesion ablation (26%, 61 of
239 men) (Table 3). Based on univariate analysis, being in
the NCCN high-risk group was a statistically significant
predictive factor for men not suitable for focal therapy,
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Fig. 1 – Template prostate-mapping biopsies. (a) Biopsies are taken every 5 mm through a template brachytherapy grid using a method described by
Winston Barzell. Biopsies are still taken every 5 mm throughout the prostate, and two biopsies are taken from the same grid coordinate if the prostate is
longer than the length of one core biopsy [19]. (b) Regional method used on template-mapping biopsy. Although 5-mm sampling is carried out, the
biopsies are batched into 20 zones to limit pathology burdens. The colour coding of individual lesions/zones is based on Kirkham et al. [19]. In this case,
index lesion ablation could be targeted to the left peripheral zone lesion and the low-volume, low-grade cancer in zone 20 left untreated. Reprinted from
[18] with permission from Elsevier.
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Fig. 2 – The morphologic characteristics of localised prostate cancers that were deemed suitable and not suitable for focal therapy: (a) unilateral disease,
hemiablation; (b) unifocal disease, unifocal ablation; (c) bilateral bifocal disease, bifocal ablation; (d and e) index lesion with low-volume, low-grade
lesion or lesions in contralateral areas, index lesion ablation; (f) bilateral high-volume or high-grade disease, not suitable for focal therapy.
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ing between low- and intermediate/high-risk groups, the
proportion of men suitable for focal therapy decreased
from 99% (84 of 85 men) to 91% (94 of 106 men),
respectively ( p = 0.005). When dichotomising between
low/intermediate-risk compared with high-risk groups,
95% (166 of 175 men) compared with 75% (12 of 16
men) were suitable for focal therapy ( p = 0.002).[(Fig._3)TD$FIG]
Fig. 3 – Flowchart demonstrating patient population characteristics.
TTPM = transperineal template prostate mapping; TRUS = transrectal
ultrasound; HIFU = high-intensity focussed ultrasound.On binary logistic regression modelling that incorporat-
ed transrectal biopsy parameters, we found no statistically
significant predictive factor for focal therapy suitability.
However, when TTPM biopsy variables were used instead,
stage (specifically, radiologic T2c) was a significant negative
predictor ( p = 0.001) (odds ratio: 0.001 [95% confidence
interval, 0.000–0.048]) (Table 5).
4. Discussion
Approximately 90% of men presenting with low- and
intermediate-risk disease in our cohort were suitable for
at least one focal therapeutic strategy using TTPM biopsy as
a means to localise individual PCa lesions.
Our study has a number of limitations. First, as a tertiary
centre, we hadmen presenting to us whowere interested in
focal therapy. This situationmight have led to selection bias,
as men with larger cancer burdens on transrectal biopsy
may not have sought further risk stratification or trials in
focal therapy. This bias is difficult to quantify. Second, as
there is no clear consensus as to which risk category for
focal therapy should be investigated [3–6,15,16], our
inclusion of intermediate- and high-risk groups may be
controversial. We have tried to reflect this lack of consensus
by describing all risk groups in an open manner. Third,
although we found that clinical T stage was the only
negative predictor for suitability of focal therapy, it must be
noted that clinical T stage does not correlate very well with
final pathologic stage or final oncology outcome after
Table 1 – Baseline characteristics in 291 men undergoing
transperineal template prostate-mapping biopsy
Baseline characteristics Value
Age, yr, median (IQR) (overall range) 61 (9) (40–81)
Serum PSA, ng/ml, median
(IQR) (overall range)
6.8 (5.5) (2.1–24.8)
Prostate volume, ml, median
(IQR) (overall range)
35.0 (18) (15–113)
PSA density, ng/ml per cubic centimetre,
median (IQR) (overall range)
0.17 (0.14) (0.02–0.99)
Initial biopsy strategy, no. (%)
TRUS biopsy 267 of 291 (92)
TTPM biopsy 24 of 291 (8)
Gleason (if positive on TRUS-guided
biopsy), no. (%)
6
3 + 3 163 of 233 (70)
7 56 of 233 (24)
3 + 4 46 of 233 (20)
4 + 3 10 of 233 (4)
Missing 17 of 233 (6)
TRUS-guided biopsies
Total cores, no., median (IQR) (overall range) 10 (4) (3–18)
Total positive cores, no., median
(IQR) (overall range)
2 (2) (1–10)
Positive cores, %, median (IQR) (overall range) 6.0 (6.5) (1.2–24.0)
MCL, mm, median (IQR) (overall range) 3 (4) (1–14)
% MCL, median (IQR) (overall range) 25 (30) (1–100)
TRUS biopsy laterality, no. (%)
Unilateral 199 of 233 (85)
Bilateral 23 of 233 (10)
Missing 11 of 233 (5)
Radiologic (MRI) stage, no. (%)
T1c 85 of 239 (36)
T2a 105 of 239 (44)
T2b 27 of 239 (11)
T2c 5 of 239 (2)
T3a 17 of 239 (7)
Risk group (NCCN) after TRUS biopsy, no. (%)
Low 102 of 233 (44)
Intermediate 98 of 233 (42)
High 16 of 233 (7)
Missing 17 of 233 (7)
IQR = interquartile range; PSA = prostate-speciﬁc antigen; TRUS = transrectal
ultrasound; TTPM = transperineal template prostate mapping; MCL =
maximum cancer length; MRI = magnetic resonance imaging; NCCN =
National Comprehensive Cancer Network.
Note: Of men with positive TRUS biopsy, 25 (12%) had a negative TTPM
biopsy.
Table 2 – Details of transperineal template prostate-mapping
biopsies in 291 men
Characteristics Value
Reason for undergoing TTPM biopsies, no. (%)
Positive TRUS biopsy 233 of 291 (80)
Risk stratiﬁcation 69 of 291 (24)
Focal therapy 164 of 291 (56)
Negative TRUS biopsy, persistent risk 34 of 291 (12)
Diagnostic (no previous TRUS biopsy) 24 of 291 (18)
TTPM biopsies
Total cores, no., median (IQR) (overall range) 29 (18) (10– 0)
Core density (biopsies per cubic centimetre),
median (IQR) (overall range)
1.1 (1.2) (0.4–7.5)
Total positive cores, no., median (IQR)
(overall range)
8 (5) (2–31)
Positive cores, %, median (IQR) (overall range) 5.2 (6.8) (0.6–74.0)
MCL, mm, median (IQR) (overall range) 6 (5) (1–15)
% MCL, median (IQR) (overall range) 50 (55) (3–100)
Gleason (TTPM biopsies), no. (%)
No cancer 52 of 291 (18)
3 + 3 96 of 291 (33)
Score 7 127 of 291 (44)
3 + 4 119 of 291 (41)
4 + 3 8 of 291 (3)
4 + 4 1 of 291 (0.3)
Not gradable 15 of 291 (5)
Risk group (NCCN) after TTPM, no. (%)
Low 70 of 239 (29)
Intermediate 144 of 239 (60)
High 20 of 239 (8)
Missing 5 of 239 (2)
TTPM laterality, no. (%)
Unilateral 94 of 239 (39)
Right 45 of 239 (19)
Left 49 of 239 (21)
Bilateral 145 of 239 (61)
TTPM = transperineal template prostate mapping; TRUS = transrectal
ultrasound; IQR = interquartile range; MCL = maximum cancer length;
NCCN = National Comprehensive Cancer Network.
Note: Of men with positive TRUS biopsy, 25 (12%) had a negative TTPM
biopsy.
Table 3 – The proportion of men suitable for focal therapy
following positive transperineal template prostate-mapping
biopsy
Focal strategy Value, no. (%)
Suitable for focal therapy 220 of 239 (92)
Not suitable for focal therapy 19 of 239 (8)
Unilateral disease (Fig. 2a and 2b)
Suitable for focal therapy 126 of 239 (53)
Hemiablation (Fig. 2a) 53 of 239 (22)
Unifocal ablation (Fig. 2b) 73 of 239 (31)
Not suitable for focal therapy 0 (0)
Bilateral disease (Fig. 2c– 2f)
Suitable for focal therapy 94 of 239 (39)
Bilateral focal ablation (Fig. 2c) 33 of 239 (14)
Index lesion ablation only (Fig. 2d–2f) 61 of 239 (26)
Not suitable for focal therapy 19 of 239 (8)
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remember that while defining the patient population is
important and facilitates decision making in clinical
practice and research, focal therapy has no long-term
outcomes on disease control and is thus not yet considered
standard care. Finally, there is no gold standard control with
which to compare the results of TTPM biopsy; hence, the
accuracy of TTPM biopsy in tumour localisation may be
questioned. However, both simulation models [21] and a
radical prostatectomy comparison study [22] reflect a high
level of fidelity. At the same time, we acknowledge that lack
of definitive final histology could have an unquantifiable
bias in the current study.
A large study population, accurate data collection, and
mapping of individual cores of the TTPM biopsies for every
patient added strength to the study. The different focaltherapy strategies are based on our prospective trials and
are thus not just theoretical concepts. We have previously
shown that of men with low- and intermediate-risk disease
who have undergone radical prostatectomy, between 51%
and 68% would have been suitable for a form of focal
therapy including index lesion ablation [23,24]. Other
Table 4 – The relationship of suitability for focal therapy and risk groups following transperineal template prostate-mapping biopsies
NCCN category based
on TTPM biopsy
Unsuitable for
focal therapy, no. (%)
Suitable for
focal therapy, no. (%)
Low 3 of 70 (4) 67 of 70 (96) Spearman rank order correlation
(expected cell frequency <5), p = 0.017
Intermediate 10 of 140 (7) 130 of 140 (93)
High 5 of 18 (28) 13 of 18 (72)
Low 3 of 70 (4) 67 of 70 (96) Pearson chi-square, p = 0.179
Intermediate and high 15 of 158 (10) 143 of 158 (91)
Low and intermediate 13 of 210 (6) 197 of 210 (94) Spearman rank order correlation
(expected cell frequency <5), p = 0.001
High 5 of 18 (28) 13 of 18 (72)
TTPM = transperineal template prostate mapping; NCCN = National Comprehensive Cancer Network.
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of men may be suitable [25]. These differences may be due
to controversy surrounding the concept of the index lesion
and whether it is safe to leave low-grade, low-volume
lesions untreated. We have included this concept as aTable 5 – The role of transrectal biopsy and transperineal template
prostate-mapping biopsy parameters in combination with other
clinical baseline parameters to predict subsequent suitability for
focal therapy (binary logistic regression)
Variables Odds ratio p value
Variables for binary logistic regression model based
on TRUS biopsy parameters
Age 0.000 0.989
PSA 0.000 0.996
Total number of cores 0.000 0.990
Number of positive cores 0.000 0.972
Maximum cancer length <0.001 0.989
Gleason score (with respect to Gleason 6)
Gleason 7 <0.001 0.973
Volume 1.779 0.995
Stage (with respect to stage T1c) 1.000
Stage T2a 0.000 0.982
Stage T2b 0.000 0.987
Stage T2c 0.000 0.989
Stage T3a 0.000 0.991
NCCN risk (with respect to low risk) 1.000
Intermediate 0.000 0.979
High <0.001 0.995
Variables for binary logistic regression
model based on TTPM parameters
Age 1.023 0.665
PSA 0.938 0.362
Volume 0.997 0.908
Stage (with respect to stage T1c) 0.007
Stage T2a 0.253 0.298
Stage T2b 0.041 0.084
Stage T2c 0.001 0.001
Stage T3a 0.000 1.000
NCCN risk (with respect to low risk) 0.835
Intermediate 2.306 0.548
High <0.001 1.000
Total number of cores 1.019 0.475
Number of positive cores 0.937 0.254
Maximum cancer length 0.870 0.481
TTPM Gleason score (with respect to Gleason 6) 0.943
Gleason 7 1.472 0.733
Gleason 8 0.000 1.000
TRUS = transrectal ultrasound; TTPM = transperineal template prostate
mapping;
PSA = prostate-speciﬁc antigen; NCCN = National Comprehensive Cancer
Network.focal therapeutic strategy, since men are currently being
treated in this manner within the context of ethics
committee–approved trials [17–19]. Indeed, many focal
therapy series in which transrectal biopsy is used to localise
lesions are likely to be treating by an index lesion ablation
de facto.
Our studyhas relevance on a number of levels. First, when
patientswish to explore focal therapy and are recommended
to have a general anaesthetic and multiple biopsies, which
carry some additional toxicity, they are likely to want to
know the odds that they might be found to have suitable
disease for focal therapy. Second, physicians offering
template biopsies with a view to focal therapy are better
placed to advise and counsel while also being able to make a
judgement on whether the additional resources are worth-
while for their particular health care setting. Third, with
designs for randomised controlled trials of focal therapy
compared with radical therapy being considered, there is a
key issueaboutwhen toapply a templatebiopsywith respect
to the timing of randomisation. If template biopsies are
conducted prior to randomisation, men potentially go
through a morbid, high-burden test that will have little
clinical relevance if they are randomised to the control arm. If
templates are conducted after randomisation and only in the
focal arm, but a large proportion ofmen are then not suitable
for focal therapy (therefore, they have radical therapy), this
situation would be problematic from an intention-to-treat
analysis. Our study has shown that template biopsies after
randomisationwould not necessarily lead to significant rates
of whole-gland therapy in the focal therapy arm.
There are no widely accepted standards for disease
localisation in focal therapy, since studies have shown that
transrectal biopsy on its own is not sufficient [26]. However,
TTPM biopsy is more invasive and requires considerable
health care resources. Itsmajor advantage is high sensitivity
and negative predictive value for detecting and ruling out
lesions with 0.5-ml volume [28]. Since our early focal
therapy trials formed some of the first trials and followed a
phased programme [27], we decided to use TTPM biopsy to
ensure, with a high degree of confidence, that clinically
significant disease was not left untreated. Since then,
evidence on multiparametric MRI shows that this modality
might have negative predictive values of 90–95% for ruling
out clinically significant PCa (Gleason 3 + 4 and/or lesion
0.5 ml) using whole-mount prostatectomy [28,29] or
E U RO P E AN URO LOG Y 6 6 ( 2 0 1 4 ) 1 2 – 1 918TTPM [30] as a reference standard and thus might have a
role in focal therapy disease localisation.
5. Conclusions
The success of tissue-preserving focal therapy is dependent
on appropriate patient selection. This selection necessitates
an accurate investigative tool that can exclude significant
cancer outside the area intended to be ablated while
precisely localising individual cancer lesions, which are to
be selectively destroyed. When such a test, TTPM biopsy,
was applied to men with low- and intermediate-risk PCa,
most men were found to be suitable for a tissue preserva-
tion strategy. Whether such a tissue-preserving strategy
gives long-term favourable oncologic outcomes is currently
being evaluated by various ongoing focal therapy trials.
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